Characterization of a new TEM-derived beta-lactamase produced in a Serratia marcescens strain
Author(s) -
Mariagrazia Perilli,
Antonio Felici,
Nicola Franceschini,
Augusta De Santis,
Laura Pagani,
Francesco Luzzaro,
A Oratore,
Gian María Rossolini,
James R. Knox,
Gianfranco Amicosante
Publication year - 1997
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.41.11.2374
Subject(s) - aztreonam , serratia marcescens , ceftazidime , clavulanic acid , enzyme , microbiology and biotechnology , amp resistance , strain (injury) , point mutation , biology , cefotaxime , tripeptide , enzyme kinetics , chemistry , ampicillin , bacteria , biochemistry , escherichia coli , antibiotics , amino acid , gene , genetics , mutation , active site , amoxicillin , anatomy , pseudomonas aeruginosa
A natural TEM variant beta-lactamase was isolated from an epidemic strain of Serratia marcescens. Nucleotide gene sequencing revealed multiple point mutations located in the 42-to-44 tripeptide and positions 145 to 146, 178, and 238. In addition, a glutamic acid 212 deletion was also found. The purified enzyme was studied from a kinetic point of view, revealing the highest catalytic efficiency (k[cat]/Km) values for ceftazidime and aztreonam compared with the TEM-1 prototype enzyme. The in vitro resistance correlated with kinetic parameters, and the enzyme also mediated resistance to some penicillins and an ampicillin-clavulanic acid combination. The mutational and kinetic changes are discussed in relation to the three-dimensional crystallographic structure of the wild-type TEM-1 enzyme.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom